retina

‘Ideal’ disease control leads to better nAMD outcomesNeovascular age-related macular degeneration (nAMD) is well-known as a heterogeneous disease with variable natural history and variable treatment response, said Carl D. Regillo, MD, FACS. Many patients do well without monthly treatment as noted in HARBOR PRN arms.
Computer-based image analysis promising for ROPComputers may make more reliable diagnoses of plus disease in retinopathy of prematurity than individual clinicians, a researcher reports.
Paradigm shifting for ILM peeling, prone position after vitrectomyPeeling of the internal limiting membrane has increasingly become a dogma of surgical retina, while maintenance of the face-down positioning may become anachronistic in many cases.
New biomarker may predict treatment response in DMEResearchers have identified a new biomarker they believe can be used as a predictor of vision change in patients with diabetic macular edema, either during the natural history of the disease or after undergoing anti-VEGF therapy. The biomarker is disorganization of the retinal inner layers, or DRIL.
How to manage retinal disease in pregnant patients
How to manage retinal disease in pregnant patientsPregnant patients require special care and surveillance when retinal diseases are present.
Roles of Klotho and Endothelin-1 in pseudoexfoliationSerum and aqueous levels of Klotho levels are reduced in pseudoexfoliation syndrome (PXF) and pseudoexfoliative glaucoma (PEG) while Endothelin-1 (ET-1) is increased, researchers say.
16 most popular stories of 2016
16 most popular stories of 2016Here is your roundup of what made top news in 2016!
New study affirms promise of anti-integrin drug for DME
New study affirms promise of anti-integrin drug for DMEA new class of ophthalmic drug continues to show promise for treating patients with diabetic macular edema (DME).
Future of DME resting on new mechanisms of actionWhen it comes to finding new treatments for diabetic macular edema (DME), there is no shortage of promising targets, said Peter A. Campochiaro, MD. He presented an overview of future compounds with various mechanisms of action that may change how clinicians treat DME.
Introducing 3-D OCT to live surgery
Introducing 3-D OCT to live surgeryThe advent of three-dimensional optical coherence tomography to live surgery may bring greater clarity to how ophthalmologists visualize structures and how they operate.